Insight Capital Research & Management Inc. Purchases New Position in Icon Plc (ICLR)

Insight Capital Research & Management Inc. purchased a new stake in Icon Plc (NASDAQ:ICLR) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 11,934 shares of the medical research company’s stock, valued at approximately $1,359,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Janney Montgomery Scott LLC lifted its stake in shares of Icon by 11.1% in the 3rd quarter. Janney Montgomery Scott LLC now owns 12,237 shares of the medical research company’s stock valued at $1,394,000 after acquiring an additional 1,222 shares during the last quarter. Cubist Systematic Strategies LLC lifted its stake in shares of Icon by 92.8% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 9,339 shares of the medical research company’s stock valued at $1,064,000 after acquiring an additional 4,495 shares during the last quarter. Vident Investment Advisory LLC lifted its stake in shares of Icon by 248.8% in the 3rd quarter. Vident Investment Advisory LLC now owns 35,263 shares of the medical research company’s stock valued at $4,016,000 after acquiring an additional 25,152 shares during the last quarter. First Republic Investment Management Inc. lifted its stake in shares of Icon by 22.3% in the 3rd quarter. First Republic Investment Management Inc. now owns 7,988 shares of the medical research company’s stock valued at $910,000 after acquiring an additional 1,458 shares during the last quarter. Finally, Lenox Wealth Management Inc. lifted its stake in shares of Icon by 24.1% in the 3rd quarter. Lenox Wealth Management Inc. now owns 8,350 shares of the medical research company’s stock valued at $950,000 after acquiring an additional 1,624 shares during the last quarter. Institutional investors own 89.95% of the company’s stock.

Icon Plc (NASDAQ:ICLR) opened at $111.18 on Tuesday. The stock has a market capitalization of $6,020.00, a price-to-earnings ratio of 21.48, a P/E/G ratio of 1.73 and a beta of 0.61. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31. Icon Plc has a 12-month low of $73.76 and a 12-month high of $124.48.

Icon (NASDAQ:ICLR) last announced its earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.03. Icon had a return on equity of 28.42% and a net margin of 16.37%. The business had revenue of $440.30 million during the quarter, compared to analyst estimates of $438.09 million. During the same period last year, the company earned $1.19 EPS. Icon’s revenue for the quarter was up 4.8% compared to the same quarter last year. equities research analysts anticipate that Icon Plc will post 5.36 earnings per share for the current year.

Several brokerages recently issued reports on ICLR. KeyCorp reaffirmed an “overweight” rating and set a $125.00 target price (up from $115.00) on shares of Icon in a research report on Monday, November 13th. They noted that the move was a valuation call. Zacks Investment Research lowered Icon from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. SunTrust Banks reaffirmed a “buy” rating and set a $138.00 target price on shares of Icon in a research report on Sunday, October 29th. Barclays raised their target price on Icon from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Friday, October 27th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $120.00 target price (up from $105.00) on shares of Icon in a research report on Monday, October 16th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. Icon currently has an average rating of “Buy” and an average price target of $121.00.

ILLEGAL ACTIVITY NOTICE: “Insight Capital Research & Management Inc. Purchases New Position in Icon Plc (ICLR)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/12/insight-capital-research-management-inc-purchases-new-position-in-icon-plc-iclr.html.

About Icon

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply